Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

ClinicalTrials.gov ID: NCT01276704

Public ClinicalTrials.gov record NCT01276704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.

Study identification

NCT ID
NCT01276704
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Carol Fabian, MD
Other
Enrollment
180 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
21 Years to 49 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Jun 30, 2017
Completion
Jun 30, 2017
Last update posted
Sep 20, 2023

2011 – 2017

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
Northwestern University Medical Center Chicago Illinois 60611
University of Kansas Medical Center Kansas City Kansas 66160
Dana Farber Cancer Institute Boston Massachusetts 02215
Ohio State Unviersity Medical Center Columbus Ohio 43210
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104
University of Washington Seattle Washington 98109-1023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01276704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 20, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01276704 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →